Immutopics

San Clemente, United States Founded: 1989 • Age: 37 yrs Acquired By Quidel
Immunoassays for bone health assessment are developed and marketed.
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 11 Brand Intelligence

About Immutopics

Immutopics is a company based in San Clemente (United States) founded in 1989 was acquired by Quidel in March 2016. Immutopics operates in a competitive market with competitors including Abcam, Stem Cell Technologies, GenScript, Sino Biological and Miltenyi Biotec, among others.

  • Headquarter San Clemente, United States
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    Not available
  • Acquired by
    Quidel

    (Mar 18, 2016)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Immutopics

Premium access

Detailed funding history for Immutopics

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investors in Immutopics

Immutopics has secured backing from 1 investor. Prominent investors backing the company include QuidelOrtho.

All
Investor Description Founded Year Domain Location
QuidelOrtho is engaged in providing diagnostic testing solutions globally.
Locked Locked Locked
Premium access

Investor details for Immutopics

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Immutopics

Investments
Premium access

Investment portfolio details for Immutopics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Immutopics

Premium access

Detailed financials for Immutopics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Immutopics Comparisons

Immutopics Primary company
Description
Immunoassays for bone health assessment are developed and ma...
Location
San Clemente, United States
Founded Year
1989
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Immutopics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Immutopics

Immutopics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abcam, Stem Cell Technologies, GenScript, Sino Biological and Miltenyi Biotec, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Biological reagents and antibodies are developed for life science research.
Locked Locked Locked
Developer of cell culture media and ancillary reagents for life science research
Locked Locked Locked
Reagents and instruments are provided for life sciences research.
Locked Locked Locked
Reagents and kits are provided for clinical research applications.
Locked Locked Locked
Develops tools and products for research and clinical application
Locked Locked Locked
Provider of molecular diagnostic kits for cancer, hereditary diseases, and reproductive disorders
Premium access

Detailed competitors of Immutopics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Immutopics

Premium access

Complete news archive for Immutopics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Immutopics

Immutopics was founded in 1989.

Immutopics is headquartered in San Clemente, United States. It is registered at San Clemente, California, United States.

Immutopics develops, manufactures and markets immunoassays for assessing bone health to the research and scientific communities. Its product line includes ELISA kit for the determination of Human fibroblast Growth Factor-23 levels in plasma or cell culture media, ELISA kit for quantitative determination of Human Intact FGF-23 levels, ELISA kit for Human Bioactive Intact PTH levels, ELISA kit for quantitative determination of Human parathyroid hormone 1-34 levels, and ELISA kit for detection of Anti-Human PTH (1-34) antibodies in Serum, Plasma or Cell culture media. The company got acquired by Diagnostic Hybrids, Inc., a wholly owned subsidiary of Quidel Corporation, on March 18, 2016.

Immutopics's top competitors include Abcam, Sino Biological and Meridian Bioscience.

Immutopics has 1 investor. Key investors include QuidelOrtho.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available